- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr. Strosberg on NETTER-1 Trial Results for Midgut NETs
Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors.
Jonathan R. Strosberg, MD, medical oncologist, Department of Gastrointestinal Oncology, section head, Neuroendocrine Division, chair, Gastrointestinal Department Research Program, Moffitt Cancer Center, discusses results of the phase III NETTER-1 trial for midgut neuroendocrine tumors (NETs).
The NETTER-1 trial compared the efficacy of 177-Lu-Dotatate (Lutathera) with octreotide (Sandostatin LAR) in patients with advanced progressive disease. Results showed that the median progression-free survival (PFS), the trial's primary endpoint, improved by 80% (HR, .21). The median time-to-progression with high-dose octreotide was 8.7 months and not yet reached in the 177-Lu-Dotatate arm at a median follow-up of 18 months. Strosberg predicts that the median PFS will be at approximately 40 months.
There was a strong improvement in overall survival, the secondary endpoint, (P <.018). Though these results are encouraging, it does not meet the significance threshold for a preliminary analysis of survival, Strosberg explains.
<<<